Evaluation and Management of Drug-Drug Interactions in Patients Hospitalized in Nephrology and Post-Transplant Wards in a Teaching Hospital
Background: Kidney transplant patients usually take a combination of medications after transplantation; hence, medication safety becomes an important issue in order to maintain the new organ working properly. To evaluate the incidence and risk factors associated with potential drug-drug interactions (pDDIs) in hospitalized patients in Nephrology and Post-transplant wards to improve clinical management of pDDIs by a clinical pharmacist.
Methods: In this cross-sectional study, patients in Nephrology and Post-transplant wards were screened for pDDIs, using the interaction screening program Lexi-comp resource®. After evaluating the detected pDDIs for clinical relevance, the intervention was performed through physicians or nurses for type D and X drug interactions. Intervention feedback, implemented recommendations, and any probable adverse drug reactions were documented.
Results: During the study, 399 patients (239 in nephrology and 160 in post-transplant wards) plus 6105 drug orders were evaluated, and a total of 3263 DDIs were identified; of them, 827 (23.5%) were determined to be D and X classifications, and a total of 89.97% of all hospitalized cases had at least 1 pDDIs. Factors that had the greatest influence on pDDI incidence included the number of drugs and the admitted wards. Patients in the post-transplant ward experienced 2.3 times more DDIs than those in the nephrology ward. In total, 78% of class X and D DDIs required intervention, of which 75% were accepted and implemented by the physicians and nurses.
Conclusion: Clinically relevant pDDIs are common in patients in Nephrology and Post-transplant wards, and pharmacists play a critical role in detecting and managing this medical problem in hospitalized patients.
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-9.
3. Wheeler AJ, Scahill S, Hopcroft D, Stapleton H. Reducing medication errors at transitions of care is everyone's business. Aust Prescr 2018;41(3):73-7.
4. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36(9):1331-6.
5. Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Marín-Gil R, Villacorta-Linaza P. Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 2012;34(6):807-17.
6. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65(8):757-73.
7. Wang HY, Chan AL, Chen M, Liao C, Tian Y. Effects of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics. Transplant Proc 2008;40(7):2319-23.
8. Peter WLS. Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation. Adv Chronic Kidney Dis 2010;17(5):413-9.
9. Kaplan B, Mason NA, Shimp LA, Ascione FJ. Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharmacother 1994;28(3):316-9.
10. Mirkov S. Implementation of a pharmacist medication review clinic for haemodialysis patients. N Z Med J 2009;122(1297):25-37.
11. Mason NA, Bakus JL. Strategies for reducing polypharmacy and other medication‐related problems in chronic kidney disease. Semin Dial 2010;23(1);55-61.
12. Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168(17):1890-6.
13. Ghods AJ. The history of organ donation and transplantation in Iran. Exp Clin Transplant 2014;12(suppl 1):38-41.
14. Saidi RF, Broumand B. Current challenges of kidney transplantation in Iran: Moving beyond the “Iranian Model”. Transplantation 2018;102(8):1195-7.
15. Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens 2009;18(5):404-11.
16. Qiu C, Huang Y, Wang Q, et al. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin Infect Dis 2012;54(1):17-24.
17. Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian J Pharm Sci 2012;74(1):63-8.
18. Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17(4):123-32.
19. MacKinnon NJ, Hepler CD. Preventable Drug-related Morbidity in Older Adults-1. Indicator Development. J Manag Care Pharm 2002;8(5):365-71.
20. Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005;46(4):669-80.
21. Joshua L, Devi PD, Guido S. Adverse drug reactions in nephrology ward inpatients of a tertiary care hospital. Indian J Med Sci 2007;61(10):562-9.
22. Pranabjyoti M, DM M. Profile of Adverse Drug Reaction in Patients with Renal Disorders. International Journal of Health Research and Medico Legal Practice 2017;3(1):51-4.
23. Dopour A, Hosseini F, Kanki K, Davoodpour S, Srinivas C, Shekar H. Prospective study on identification and assessment of potential drug-drug interactions in emergency medicine department at KIMS hospital and research centre. International Journal of Research in Pharmacy and Science 2016;6(1):36-39.
24. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug‐drug interactions in hospitalized patients. J Clin Pharmacol 2011;51(7):1043-50.
25. Mannesse CK, Derkx F, De Ridder M, Man In't Veld A, Van Der Cammen T. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000;29(1):35-9.
26. Namazi S, Pourhatami S, Borhani-Haghighi A, Roosta S. Incidence of potential drug-drug interaction and related factors in hospitalized neurological patients in two Iranian teaching hospitals. Iran J Med Sci 2014;39(6):515-21.
27. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci 2009;12(3):266-72.
28. Shafiekhani M, Karimi S, Davarpanah Ma, Vazin A. Evaluating drug interactions, adverse drug reactions, and level of adherence to highly active antiretroviral therapy regimen amongst HIV-positive patients who referred to an AIDS healthcare center in Fars, southern Iran: the first multifaceted study from Iran. HIV &m AIDS Review. International Journal of HIV-Related Problems 2017;16(1):24-31.
29. Jankovic SM, Pejcic AV, Milosavljevic MN, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care 2018;43:1-6.
30. Köhler G, Bode-Böger S, Busse R, Hoopmann M, Welte T, Böger R. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38(11):504-13.
31. Riechelmann RP, Moreira F, Smaletz Ò, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005;56(3):286-90.
32. Sharma S, Chhetri HP, Alam K. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol 2014;46(2):152-6.
33. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. European Journal of Internal Medicine 2008;19(6):413-20.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.